Multiple System Atrophy clinical trials
34 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
- A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
- A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
- Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
- A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
- Treatment of Supine Hypertension in Autonomic Failure (CPAP)
- Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension
- CPAP for the Treatment of Supine Hypertension
- Neurologic Stem Cell Treatment Study
- Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
- Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
- CW2IP2: Imaging and Diagnostic Assessments
- PET Tau - Neurodegenerative Disease Imaging
- Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
- Multiple System Atrophy Multidisciplinary Clinic
- The CurePSP Genetics Program
- Parkinson's Disease Biomarkers in Nerve Cells in the Gut
- Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging
- NYSCF Scientific Discovery Biobank
- Modifiable Variables in Parkinsonism (MVP)
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
- Natural History Study of Synucleinopathies
- PET Imaging Evaluation of [11C]SY08
- [18F]F-DOPA Imaging in Patients With Autonomic Failure
- Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
- Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
- Remote Monitoring in Progressive Supranuclear Palsy (PSP)
- Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease
- AB-1005 Long-Term Follow-up Study
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
- Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
- North American Prodromal Synucleinopathy Consortium Stage 2
- Gait Analysis in Neurological Disease
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Multiple System Atrophy” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.